“I knew nothing about the MAINCHANCE outcome prior to exercising my share options,” said Ms. DeCashaway, “and neither did my financial advisor. After all, I’m only a senior company director. Why would I bother myself with trivia such as the details of a pivotal clinical study for a major new product that the company’s future depended upon? Senior executives such as myself are never interested in minutiae like that…”
Continue reading at PharmaGiles.
Comments